Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

Por Pili, R, Salumbides, B, Zhao, M, Altiok, S, Qian, D, Zwiebel, J, Carducci, M A, Rudek, M A
Publicado em 2012

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Por Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Publicado no Br J Cancer (2015)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

Por Garrido-Laguna, I, Tan, A C, Uson, M, Angenendt, M, Ma, W W, Villaroel, M C, Zhao, M, Rajeshkumar, N V, Jimeno, A, Donehower, R, Iacobuzio-Donahue, C, Barrett, M, Rudek, M A, Rubio-Viqueira, B, Laheru, D, Hidalgo, M
Publicado em 2010